Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company developing drug reformulations and mucosal delivery approaches for diseases with significant unmet need. News about LIPO centers on its liposomal tacrolimus oral-rinse programs, including clinical data in oral lichen planus, and on CMC manufacturing work for LP-10 and LP-310.
Company updates also cover patent protection for MRI-based diagnostic technology, presentations of study results at medical and investor forums, and corporate-status developments after the delisting of its common stock from the Nasdaq Capital Market. Lipella later reported voluntary Chapter 11 petitions by the company and certain subsidiaries.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.